NCT03645460View on ClinicalTrials.gov

Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)

NARecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)
Interventions
GENETIC

Direct intravenous injection of ivlv-ADA lentiviral vector

Injection of ivlv-ADA lentiviral vector at \~1x10\^9 per kg body weight

Trial Locations (2)

518000

RECRUITING

Shenzhen Geno-immune Medical Institute, Shenzhen

Unknown

RECRUITING

Guilin Hospital of Chinese Traditional and Western Medicine, Guilin

All Listed Sponsors
lead

Shenzhen Geno-Immune Medical Institute

OTHER